Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs The Vita Coco Company Inc (COCO) Price & Performance

ADMA Biologics Inc
The Vita Coco Company Inc

Price performance

Price movement over the last 24 hours

Key statistics

ADMA Biologics Inc vs The Vita Coco Company Inc — how do they compare? ADMA Biologics Inc trades at $9.29 (market cap $2.13B), while The Vita Coco Company Inc trades at $66.61 (market cap $3.74B). The key difference: The Vita Coco Company Inc is the larger of the two by market cap, and The Vita Coco Company Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ADMACOCO
Market Cap
$2.13B$3.74B
Sector
HealthTechnology
52-Week High
$20.38$84.02
52-Week Low
$7.60$32.30
Enterprise Value
$2.20B$3.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

The Vita Coco Company Inc

COCO trades at $66.78, up 0.94% today, with a bullish technical signal driven by oversold RSI readings but bearish moving averages. The company reported strong Q1 2026 EPS of $0.50, beating expectations, and shows robust profitability with a 12.59% net margin and 26.32% ROE. Recent news highlights market dominance in coconut water and expanded partnerships, supporting growth prospects amid a $125 billion market opportunity.

Outlook is positive with a consensus price target of $79.33, implying 19% upside, though high valuation multiples (P/E 48.39) and competitive pressures pose risks. Investors should weigh strong earnings momentum against potential volatility from sector rotation and margin pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About The Vita Coco Company Inc

The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.

Read more on COCO